Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Corydaline is a bioactive and naturally occurring isoquinoline alkaloid extracted from Corydalis yanhusuo. It exhibits anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities by acting as an AChE inhibitor.
Targets |
AChE (IC50 = 226 µM); μ Opioid Receptor/MOR
|
---|---|
ln Vitro |
Corydaline treatment (12.5-50 μM; 24 hours) reduces COX-2 production and activation of JNK MAPK and P38 MAPK, but not ERK MAPK, which prevents EV71 replication [2].
|
ln Vivo |
Corydanine (10 mg/kg; subcutaneous; once) therapy revealed analgesic effects by dramatically decreasing writhing behavior in mice [3].
|
Enzyme Assay |
Enterovirus 71 (EV71) is a huge threat to the worldwide public health and there is no approved antiviral drug for EV71-induced disease therapy. Corydaline exists antiallergic and antinociceptive activities, but the anti-EV71 activity of corydaline is still not reported. In this study, corydaline could suppress the expression of viral structural and non-structural proteins. Furthermore, corydaline inhibits EV71 replication by suppressing the COX-2 expression and the phosphorylation of JNK MAPK and P38 MAPK but not ERK MAPK in vitro. Based on these findings, corydaline could be a potential lead or supplement for the development of new anti-EV71 agents in the future[2].
Pain remains a key therapeutic area with intensive efforts directed toward finding effective and safer analgesics in light of the ongoing opioid crisis. Amongst the neurotransmitter systems involved in pain perception and modulation, the mu-opioid receptor (MOR), a G protein-coupled receptor, represents one of the most important targets for achieving effective pain relief. Most clinically used opioid analgesics are agonists to the MOR, but they can also cause severe side effects. Medicinal plants represent important sources of new drug candidates, with morphine and its semisynthetic analogues as well-known examples as analgesic drugs. In this study, combining in silico (pharmacophore-based virtual screening and docking) and pharmacological (in vitro binding and functional assays, and behavioral tests) approaches, we report on the discovery of two naturally occurring plant alkaloids, corydine and corydaline, as new MOR agonists that produce antinociceptive effects in mice after subcutaneous administration via a MOR-dependent mechanism. Furthermore, corydine and corydaline were identified as G protein-biased agonists to the MOR without inducing β-arrestin2 recruitment upon receptor activation. Thus, these new scaffolds represent valuable starting points for future chemical optimization towards the development of novel opioid analgesics, which may exhibit improved therapeutic profiles[3]. |
Cell Assay |
Western Blot analysis [2]
Cell Types: Vero cells infected with EV71 Tested Concentrations: 12.5μM, 25μM, 50μM Incubation Duration: 24 hrs (hours) Experimental Results: The phosphorylation and expression of P38MAPK and JNKMAPK were diminished. COX-2. |
Animal Protocol |
Animal/Disease Models: Male CD1 mice (30-35 g, 7-8 weeks old) were injected with acetic acid [3].
Doses: 10 mg/kg. Route of Administration: subcutaneousadministration; primary Experimental Results:demonstrated anti-nociceptive effect on mice. |
References |
[1]. Hai-Tao Xiao, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011 Sep;25(15):1418-22.
[2]. Hui-Qiang Wang, et al. Corydaline inhibits enterovirus 71 replication by regulating COX-2 expression. J Asian Nat Prod Res. 2017 Nov;19(11):1124-1133. [3]. Teresa Kaserer, et al. Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists. Sci Rep. 2020 Aug 14;10(1):13804. |
Molecular Formula |
C22H27NO4
|
---|---|
Molecular Weight |
369.4541
|
Exact Mass |
369.194
|
Elemental Analysis |
C, 71.52; H, 7.37; N, 3.79; O, 17.32
|
CAS # |
518-69-4
|
Appearance |
Typically exists as white to light yellow solids at room temperature
|
Density |
1.2±0.1 g/cm3
|
Boiling Point |
482.3±45.0 °C at 760 mmHg
|
Melting Point |
135°C
|
Flash Point |
135.7±25.9 °C
|
Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
Index of Refraction |
1.6
|
LogP |
4.2
|
tPSA |
40.16
|
SMILES |
O(C([H])([H])[H])C1=C(C([H])=C([H])C2=C1C([H])([H])N1C([H])([H])C([H])([H])C3=C([H])C(=C(C([H])=C3[C@@]1([H])[C@@]2([H])C([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
InChi Key |
VRSRXLJTYQVOHC-YEJXKQKISA-N
|
InChi Code |
InChI=1S/C22H27NO4/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23/h6-7,10-11,13,21H,8-9,12H2,1-5H3/t13-,21+/m0/s1
|
Chemical Name |
(13S,13aR)-2,3,9,10-tetramethoxy-13-methyl-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline
|
Synonyms |
Corydalin; BRN 0096972; NSC 406036; BRN-0096972; NSC-406036; BRN0096972; NSC406036
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~90.22 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7067 mL | 13.5336 mL | 27.0673 mL | |
5 mM | 0.5413 mL | 2.7067 mL | 5.4135 mL | |
10 mM | 0.2707 mL | 1.3534 mL | 2.7067 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.